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Abstract
Many people pursue direct-to-consumer (DTC) DNA testing to learn about
health risks. While DTC testing for breast cancer genes BRCA1 and BRCA2 may
provide vital information to those testing positive, it is unclear whether
individuals testing negative understand the implications of these results.
Furthermore, it is unknown how such findings may influence future cancer risk
management. Ninety-six individuals who underwent BRCA testing through the
DTC service, 23andMe, completed a survey designed to assess their
understanding of a negative result and how this result may impact cancer risk
management. Respondents were recruited via social media sources Reddit and
Facebook. All participants tested negative for the three BRCA variants
analyzed by 23andMe: BRCA1 185delAG, BRCA1 5382insC, and BRCA2 6174delT.
Six questions assessed understanding of the limitations of the testing. Results
indicated that 77.1% of respondents answered five or more questions correctly,
confirming participants adequately understood testing limitations. While 92%
of participants reported their results would not alter the frequency of their
cancer screenings, analysis of variance indicated that lower understanding of
testing limitations was associated with less clarity about how to proceed with
cancer risk management, F (2, 93) = 5.98, p < .05. Analyses were conducted to
identify factors contributing to overall understanding scores. Significant
correlates of understanding were age and education level. Participants’
perceived risk played a role in both their understanding and future cancer
screening behavior. This observation necessitates further study.

Introduction
• Direct-to-consumer genetic testing (DTCGT) allows consumers access to
their genetic information outside of the healthcare world.
• 23andMe was the first DTCGT company to receive FDA approval to analyze
breast cancer genes BRCA1 and BRCA2.
• Pathogenic variants in the BRCA genes cause Hereditary Breast and Ovarian
Cancer Syndrome (HBOC) which drastically increases an individuals’ lifetime
risk of cancer (breast, ovarian, prostate, pancreatic, and melanoma) over
that of the general population.
• Limitations to DTC BRCA testing:
• Only three Ashkenazi Jewish founder mutations analyzed:
• BRCA1 185delAG
• BRCA1 5382insC
• BRCA2 6174delT
• Common in the Ashkenazi Jewish population but rare in the
general population.
• >1000 disease causing variants in the BRCA genes have been
identified.
• Only BRCA genes are examined:
• Dozens of other cancer predisposition genes have been
identified.
• Speculations that consumers do not understand the limitations of DTC BRCA
testing and may feel falsely reassured by a negative result have been made.

Research Aims
• Determine participant’s understanding of a negative 23andMe BRCA test
result
• Examine whether participants use negative results to impact cancer risk
management

Methods
• 55-question fixed-choice survey
• Distributed via social
media
• Inclusion criteria:
• Consent to survey
• 18 years of age
• Chose to view BRCA report
• Tested BRCA1/2 negative
• Recruitment though Reddit and
Facebook
• Active for 6 weeks
• 115 individuals recruited
• 7 individuals did not
meet inclusion criteria
• 12 individuals did not
complete survey
• 96 respondents for data analysis
• Demographics displayed in Table 1.

Demographics
Table 1. Demographics

Exploratory Analyses
n

%

Total

96

Gender
Male
Female
Other
Prefer not to answer

12
82
1
1

12.5%
85.4%
1.0%
1.0%

Age
<20
20-29
30-39
40-49
50-59
60-69
>70

4
41
31
9
9
1
1

4.2%
42.7%
32.3%
9.4%
9.4%
1.0%
1.0%

Education Level
High school graduate, diploma or the equivalent
Some college of vocational training
Associate’s degree
Bachelor’s degree
Master’s degree
Professional or doctoral degree

5
16
9
36
21
9

5.2%
16.7%
9.4%
37.5%
21.9%
9.4%

Ashkenazi Jewish Ancestry
Yes
No
Unsure

26
69
1

27.1%
71.9%
1.0%

Ethnicity
White
Asian
Multiracial
Other
Prefer not to answer

81
4
9
1
1

84.4%
4.2%
9.4%
1.0%
1.0%

Results
• Participant Understanding:
• Six questions asked to gauge participant’s understanding of the
limitations of DTC BRCA testing:
• What do you understand about the testing?
• Are BRCA1 and BRCA2 the only known cancer susceptibility
genes?
• Could you still be at risk for having a mutation in your BRCA1 or
BRCA2 genes after testing negative through 23andMe?
• Could you still be at risk for having a mutation in a different
cancer susceptibility gene after testing negative through
23andMe?
• Could anyone in your family still be at risk for having a mutation
in their BRCA1 or BRCA2 genes after you test negative through
23andMe?
• Can a person’s ethnicity influence how likely they are to be a
BRCA1/2 carrier?
• Answers were dichotomously
Table 2.
n
%
Understanding Score
scored and an additive metric
was applied.
Total
96
• Scores displayed in Table 2.
Understanding Score
0
1
1.0%
• Average score = 5.1 +/- 1.4
1
3
3.1%
2
4
4.2%
• Adequate understanding of
3
3
3.1%
the limitations of DTC BRCA
4
11
11.5%
5
20
20.8%
testing
6
54
56.3%
• Cancer Risk Management:
• Assessed by a single item
• Participants asked how negative BRCA results would alter cancer
screenings
• 91.7% reported they would not change cancer screenings based
on negative results
• 4.2% planned to increase vigilance
• 4.2% were unsure
• No participants reported decreasing cancer screenings
• Individuals who were unsure how their results would affect
screening behavior had a lesser understanding of the testing
• F (2, 93) = 5.98, p < .05.

• Identify factors predictive of participants’ understanding:
• Age and education level were significantly correlated:
• Individuals under the age of 40 (n=76) scored significantly
better than individuals over the age of 40 (n=20)
• F (1,94) = 6.390, p < .05
• A significantly positive correlation was seen between
participant’s education levels and understanding.
• r = .215, p < .05
• Recruitment source, gender, and ethnicity were not indicative of
respondent’s level of understanding
• Perceived risk, understanding and preventative behavior:
• Risk score calculated
• Respondents asked to gauge their risk to develop cancer based
on:
• BRCA results
• Family history
• Personal habits
• Significant positive correlation between perceived risk and
understanding
• Individuals who reported more vigilant cancer screening perceived
themselves to be at higher risk
• Interaction not significant (possibly due to small sample size)
• First Degree Relatives (FDR)
• FDR diagnosed with BRCA related cancer (n=30) perceived their
overall risk to be higher than those without an affected FDR (n=66)
• F (1,94) = 6.715, p < .05
• Individuals with an affected relative had a better understanding of
the limitations of DTCGT
• F (1,94) = 5.471, p < .05
• Raw Data Analysis
• 58.8% analyzed their raw data through a secondary source
• No significant difference noted in understanding between those
who analyzed their raw data and those who did not

Discussion
• Majority of individuals in this population:
• Understood limitations of DTC BRCA testing
• Would not use results to alter cancer screenings
• Promising that individuals in this population were not falsely
reassured of personal cancer risk due to negative results
• Individuals who were unsure how their results would alter
screenings had a lesser understanding of the testing.
• This is concerning as it implies that DTCGT may influence
how some individuals proceed with cancer risk
management.
• Limitations:
• Demographic data is not publicly available from 23andMe
• It is not clear what individuals are currently doing for their cancer
risk management
• Recruitment method may be biased:
• Subreddits and Facebook groups dedicated to 23andMe, genetics
and genomics were utilized
• 23andMe was the only DTC company examined

